KRAS mutation testing of tumours in adults with metastatic colorectal cancer: A systematic review and cost-effectiveness analysis

Health Technology Assessment

Volumn 18, Issue 62, 2014, Pages 1-132

  Westwood, Marie ^a   van Asselt, Thea ^b   Ramaekers, Bram ^b   Whiting, Penny ^a   Joore, Manuela ^b   Armstrong, Nigel ^a   Noake, Caro ^a   Ross, Janine ^a   Severens, Johan ^c   Kleijnen, Jos ^d  

^a KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLON RESECTION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; GENETIC PROCEDURES; HEALTH CARE COST; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; INOPERABLE CANCER; INTERMETHOD COMPARISON; LABORATORY DEVICE; LIVER METASTASIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTATIC COLORECTAL CANCER; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; POLYMERASE CHAIN REACTION SYSTEM; PREDICTIVE VALUE; PYROSEQUENCING; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; SANGER SEQUENCING; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; LIVER TUMOR; MUTATION; PATHOLOGY; PROBABILITY; SECONDARY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; GENETIC TECHNIQUES; HUMANS; LIVER NEOPLASMS; MARKOV CHAINS; MUTATION; PROTO-ONCOGENE PROTEINS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS;

EID: 84912027795     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18620     Document Type: Article

References (168)

1. National Institute for Health and Care Excellence. Cetuximab for the First-Line Treatment of Metastatic Colorectal Cancer. NICE technology appraisal guidance 176. London: NICE, 2009. URL: www. nice. org. uk/nicemedia/live/12216/45198/45198. pdf (accessed 30 November 2012).
2. Office for National Statistics. Cancer Registrations in England, 2010: Number of New Cases Diagnosed By Site. London: Office for National Statistics; 2012. URL: www. ons. gov. uk/ons/rel/vsob1/cancer-registrations-in-england/2010/2010-cancer-registrations-in-england-statisticalbulletin-2. html#tab-Number-of-new-cases-diagnosed-by-site (accessed 30 November 2012).
3. Cancer Research UK. Bowel Cancer Incidence Statistics. London: Cancer Research UK; 2012 URL: www. cancerresearchuk. org/cancer-info/cancerstats/types/bowel/incidence/uk-bowel-cancerincidence-statistics (accessed 30 November 2012).
4. Cancer Research UK. Bowel Cancer Mortality Statistics. London: Cancer Research UK; 2012. URL: www. cancerresearchuk. org/cancer-info/cancerstats/types/bowel/mortality/uk-bowel-cancermortality-statistics (accessed 30 November 2012).
5. Cancer Research UK. Bowel Cancer Survival Statistics. London: Cancer Research UK; 2012. URL: www. cancerresearchuk. org/cancer-info/cancerstats/types/bowel/survival/bowel-cancersurvival-statistics (accessed 30 November 2012).
6. National Cancer Intelligence Network. Cancer Incidence by Deprivation: England, 1995-2004. London: National Cancer Intelligence Network Coordinating Centre; 2009. URL: www. ncin. org. uk/view. aspx?rid=73 (accessed 30 November 2012).
7. Finan P, Smith J, Greenaway K, Yelland A, Scott N, Henderson J, et al. National Bowel Cancer Audit Report 2011. London: NHS Information Centre for Health and Social Care; 2011. URL: www. ic. nhs. uk/webfiles/Services/NCASP/audits%20and%20reports/Bowel_Cancer_Audit_Report_2011_interactive. pdf (accessed 30 November 2012).
8. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009; 205: 858-62. http://dx. doi. org/10. 1016/j. prp. 2009. 07. 010.
9. Cejas P, Lopez-Gomez M, Aguayo C, Madero R, de Castro Carpeno J, Belda-Iniesta C, et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 2009; 4: e8199. http://dx. doi. org/10. 1371/journal. pone. 0008199.
10. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16: 790-9. http://dx. doi. org/10. 1158/1078-0432. CCR-09-2446.
11. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011; 50: 307-12. http://dx. doi. org/10. 1002/gcc. 20854.
12. UK National External Quality Assessment Service for Molecular Genetics. KRAS Pilot EQA 2012-13. Newcastle upon Tyne: UK NEQAS for Molecular Genetics; 2012. URL: www. ukneqasmolgen. org. uk/ukneqas/index/news. html (accessed 6 December 2012).
13. Liu P, Liang H, Xue L, Yang C, Liu Y, Zhou K, et al. Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan((R))-MGB probe genotyping method. Exp Ther Med 2012; 4: 109-12.
14. Morgan SR, Whiteley J, Donald E, Smith J, Eisenberg MT, Kallam E, et al. Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples. Clin Med Insights Pathol 2012; 5: 15-22. http://dx. doi. org/10. 4137/CPath. S8798.
15. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-6. http://dx. doi. org/10. 1200/JCO. 2009. 21. 9170.
16. US Food and Drug Administration. Summary of Safety and Effectiveness Data: Therascreen® KRAS RGQ PCR Kit. 2012. URL: www. accessdata. fda. gov/cdrh_docs/pdf11/P110030b. pdf (accessed 21 May 2013).
17. QIAGEN. Therascreen KRAS RGQ PCR Kit Handbook (Version 1). 2011. [As cited in the NICE final scoping document, 2013. URL: www. nice. org. uk/nicemedia/live/13937/62336/62336. pdf (accessed 5 June 2014).].
18. QIAGEN. Therascreen KRAS Pyro Kit Handbook (Version 1). 2011. [As cited in the NICE final scoping document, 2013. URL: www. nice. org. uk/nicemedia/live/13937/62336/62336. pdf (accessed 5 June 2014).].
19. TIB MOLBIOL. LightMix Kit K-RAS Mutation Codons 12/13 (Version 110621). 2011. [As cited in the NICE final scoping document, 2013. URL: www. nice. org. uk/nicemedia/live/13937/62336/62336. pdf (accessed 5 June 2014).].
20. ViennaLab Diagnostics. KRAS StripAssay Instructions for Use. 2010. [As cited in the NICE final scoping document, 2013. URL: www. nice. org. uk/nicemedia/live/13937/62336/62336. pdf (accessed 5 June 2014).].
21. QIAGEN. Principle of Pyrosequencing Technology. 2012. [As cited in the NICE final scoping document, 2013. URL: www. pyrosequencing. com/DynPage. aspx?id=7454& mn1=1366&mn2=1367.].
22. Applied Biosystems. Overview of DNA Sequencing. 2011. [As cited in the NICE final scoping document, 2013. URL: www. appliedbiosystems. com/absite/us/en/home/applications-technologies/dna-sequencing-fragment-analysis/overview-of-dna-sequencing. html.].
23. Illumina. An Introduction to Next Generation Sequencing Technology. 2012. [As cited in the NICE final scoping document, 2013. URL: www. nice. org. uk/nicemedia/live/13937/62336/62336. pdf (accessed 5 June 2014).].
24. PrimerDesign. Beginners Guide to High Resolution Melt Analysis. 2009. [As cited in the NICE final scoping document, 2013. URL: www. nice. org. uk/nicemedia/live/13937/62336/62336. pdf (accessed 5 June 2014).].
25. Elso C, Toohey B, Reid GE, Poetter K, Simpson RJ, Foote SJ. Mutation detection using mass spectrometric separation of tiny oligonucleotide fragments. Genome Res 2002; 12: 1428-33. http://dx. doi. org/10. 1101/gr. GR-1578R.
26. Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011; 17: 4901-14. http://dx. doi. org/10. 1158/1078-0432. CCR-10-3137.
27. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17. http://dx. doi. org/10. 1056/NEJMoa0805019.
28. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-46. http://dx. doi. org/10. 1093/annonc/mdq632.
29. National Institute for Health and Care Excellence. Colorectal Cancer: the Diagnosis and Management of Colorectal Cancer. NICE clinical guideline 131. London: NICE; 2011. URL: www. nice. org. uk/nicemedia/live/13597/56957/56957. pdf (accessed 30 November 2012).
30. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A. Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010; 21(Suppl. 5): 70-7. http://dx. doi. org/10. 1093/annonc/mdq168.
31. Royal College of Pathologists. The Future Provision of Molecular Diagnostic Services for Aquired Diseases in the UK. 2010. [As cited in the NICE final scoping document, 2013. URL: www. nice. org. uk/nicemedia/live/13937/62336/62336. pdf (accessed 5 June 2014).].
32. Knijn N, Mekenkamp LJ, Klomp M, Vink-Borger ME, Tol J, Teerenstra S, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104: 1020-6. http://dx. doi. org/10. 1038/bjc. 2011. 26.
33. Richman SD, Chambers P, Seymour MT, Daly C, Grant S, Hemmings G, et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst) 2011; 34: 61-6.
34. National Institute for Health and Care Excellence. Guidance on the Use of Capecitabine and Tegafur with Uracil for Metastatic Colorectal Cancer. NICE technology appraisal guidance 61. London: NICE; 2003. URL: www. nice. org. uk/nicemedia/live/11498/32624/32624. pdf (accessed 30 November 2012).
35. European Medicines Agency. Summary of Product Characteristics: Erbitux 5 mg/ml Solution for Infusion. London: EMEA; 2009. URL: www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000558/WC500029119. pdf (accessed 30 November 2012).
36. National Institute for Health and Care Excellence. Cetuximab, Bevacizumab and Panitumumab for the Treatment of Metastatic Colorectal Cancer after First-Line Chemotherapy. NICE technology appraisal guidance 242. London: NICE, 2012. URL: www. nice. org. uk/nicemedia/live/13651/57924/57924. pdf (accessed 30 November 2012).
37. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: WHO; 1979. URL: http://whqlibdoc. who. int/offset/WHO_OFFSET_48. pdf (accessed 4 December 2012).
38. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16. http://dx. doi. org/10. 1093/jnci/92. 3. 205.
39. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-19. http://dx. doi. org/10. 1093/annonc/mdi246.
40. Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. York: University of York; 2009. URL: www. york. ac. uk/inst/crd/SysRev/! SSL!/WebHelp/SysRev3. htm (accessed 21 May 2013).
41. National Institute for Health and Care Excellence. Diagnostics Assessment Programme Manual. Machester: NICE; 2011. URL: www. nice. org. uk/media/A0B/97/DAPManualFINAL. pdf (accessed 10 July 2012).
42. Cochrane Diagnostic Test Accuracy Working Group. Handbook for DTA Reviews. The Cochrane Collaboration, 2009. URL: http://srdta. cochrane. org/handbook-dta-reviews (accessed 29 August 2013).
43. McGowan J, Sampson M, Lefebvre C. An evidence based checklist for the peer review of electronic search strategies (PRESS EBC). Evidence Based Libr Inform Prac 2010; 5: 1-6.
44. Royle P, Waugh N. Should systematic reviews include searches for published errata? Health Info Libr J 2004; 21: 14-20. http://dx. doi. org/10. 1111/j. 1471-1842. 2004. 00459. x.
45. Wright K, McDaid C. Is the retraction of journal articles in electronic journals and databases consistent and timely? A case study. 19th Cochrane Colloquium, Madrid, 19-22 October 2011.
46. Wright K, McDaid C. Reporting of article retractions in bibliographic databases and online journals. J Med Libr Assoc 2011; 99: 164-7. http://dx. doi. org/10. 3163/1536-5050. 99. 2. 010.
47. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928. http://dx. doi. org/10. 1136/bmj. d5928.
48. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-36. http://dx. doi. org/10. 7326/0003-4819-155-8-201110180-00009.
49. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PMM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005; 58: 982-90. http://dx. doi. org/10. 1016/j. jclinepi. 2005. 02. 022.
50. Harbord RM, Deeks JJ, Egger M, Whiting P, Sterne JA. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007; 8: 239-51. http://dx. doi. org/10. 1093/biostatistics/kxl004.
51. Harbord RM, Whiting P, Sterne JA, Egger M, Deeks JJ, Shang A, et al. An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol 2008; 61: 1095-103. http://dx. doi. org/10. 1016/j. jclinepi. 2007. 09. 013.
52. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47. http://dx. doi. org/10. 1016/S1470-2045(09)70330-4.
53. Kohne C, Bokemeyer C, Heeger S, Sartorius U, Rougier P, Van Cutsem E. Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): analysis of CRYSTAL and OPUS studies. J Clin Oncol 2011; 29(15 Suppl.): 3576.
54. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-14. http://dx. doi. org/10. 1016/S0140-6736(11)60613-2.
55. Xu J, Ye L, Ren L, Wei Y. A randomized, controlled trial of cetuximab plus chemotherapy for patients with kras wild-type unresectable colorectal liver-limited metastases. Ann Oncol 2012; 23: 190.
56. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, De Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-71. http://dx. doi. org/10. 1200/JCO. 2008. 20. 8397.
57. Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16: 3133-43. http://dx. doi. org/10. 3748/wjg. v16. i25. 3133.
58. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755-62. http://dx. doi. org/10. 1200/JCO. 2011. 38. 0915.
59. Merck Serono Ltd. Erbitux (Cetuximab) for the First-Line Treatment of Metastatic Colorectal Cancer: Submission to National Institute for Health and Clinical Excellence. Single technology appraisal (STA). Merck Serono Ltd; 2008. URL: www. nice. org. uk/nicemedia/live/11918/42095/42095. pdf (accessed 21 May 2013).
60. Xu J. Cetuximab in Combination with Chemotherapy for the Treatment of Metastatic Colorectal Cancer. NCT01564810. Bethesda, MD: National Library of Medicine; 2012. URL: http://clinicaltrials. gov/show/NCT01564810 (accessed 21 March 2013).
61. Health Quality Ontario. KRAS testing for anti-EGFR therapy in advanced colorectal cancer: an evidence-based and economic analysis. Ont Health Technol Assess Ser 2010; 10: 1-49.
62. Vijayaraghavan A, Efrusy MB, Goke B, Kirchner T, Santas CC, Goldberg RM. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int J Cancer 2012; 131: 438-45. http://dx. doi. org/10. 1002/ijc. 26400.
63. Behl AS, Goddard KAB, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, et al. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 2012; 104: 1785-95. http://dx. doi. org/10. 1093/jnci/djs433.
64. Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther 2010; 14: 375-84. http://dx. doi. org/10. 1007/BF03256395.
65. Blank PR, Moch H, Szucs TD, Schwenkglenks M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 2011; 17: 6338-46. http://dx. doi. org/10. 1158/1078-0432. CCR-10-2267.
66. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313: 275-83. http://dx. doi. org/10. 1136/bmj. 313. 7052. 275.
67. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65. http://dx. doi. org/10. 1056/NEJMoa0804385.
68. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFORI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37. http://dx. doi. org/10. 1200/JCO. 2004. 05. 113.
69. Merck Serono Ltd. Parametric models. In Erbitux (Cetuximab) for the First-Line Treatment of Metastatic Colorectal Cancer: Submission to National Institute for Health and Clinical Excellence. Single technology appraisal (STA). Merck Serono Ltd; 2008. Appendix H3.
70. Andreyev HJN, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85: 692-6. http://dx. doi. org/10. 1054/bjoc. 2001. 1964.
71. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-16. http://dx. doi. org/10. 1016/S0140-6736(08)60455-9.
72. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 94: 982-99. http://dx. doi. org/10. 1038/sj. bjc. 6603033.
73. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-8. http://dx. doi. org/10. 1056/NEJMoa071834.
74. Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Karapetis CS, Moore MJ, et al. A prospective economic analysis of cost-effectiveness of cetuximab for metastatic colorectal cancer patients from the NCIC CTG and AGITG CO. 17 trial. J Clin Oncol 2008; 26(155 Suppl.): 6528.
75. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-57, discussion 657-8.
76. Whiting P, Westwood M, Beynon R, Burke M, Sterne JA, Glanville J. Inclusion of methodological filters in searches for diagnostic test accuracy studies misses relevant studies. J Clin Epidemiol 2011; 64: 602-7. http://dx. doi. org/10. 1016/j. jclinepi. 2010. 07. 006.
77. University of Southampton. Combination Chemotherapy with or without Cetuximab before and after Surgery in Treating Patients with Resectable Liver Metastases Caused by Colorectal Cancer. NCT00482222. Bethesda, MD: National Library of Medicine; 2013. URL: http://ClinicalTrials. gov/show/NCT00482222 (accessed 14 May 2013).
78. Marchetti A, Pinto C, Taddei G, Clemente C, Troncone G, Russo A, et al. KRAS aKtive, an Italian network for assessment of KRAS mutations in colorectal cancer patients: results on 7, 432 cases. ASCO Meeting Abstr 2012; 30(Suppl. 15): e14042.
79. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-20. http://dx. doi. org/10. 1001/jama. 2010. 1535.
80. Han CB, Li F, Ma JT, Zou HW. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 2012; 30: 741-7. http://dx. doi. org/10. 3109/07357907. 2012. 732159.
81. Adams R, Maughan T, Smith C, Seymour M, Wilson R, Meade A, et al. Addition of cetuximab to oxalplatin-based combination chemotherapy (CT) in patients with K-ras wild-type advanced colorectal cancer (ACRC): effects on overall survival. MRC COIN (CR10) trial results. Ann Oncol 2009; 20: 15.
82. Adams R, Wilson RH, Seymour MT, Meade AM, Madi A, Cassidy J, et al. Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial. J Clin Oncol 2010; 28(15 Suppl.): 3525.
83. Adams R, Wilson R, Seymour M, Meade A, Madi A, Cassidy J, et al. Intermittent vs. continuous oxaliplatinfluoropyrimidine chemotherapy in the MRC COIN trial in advanced colorectal cancer: updated efficacy results, quality of life and potential predictive factors. 12th World Congress on Gastrointestinal Cancer, ESMO Conference 2010; 30 June-3 July 2010; Barcelona, Spain. Ann Oncol 2010; 21: vi19.
84. Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup phase III trial N0147. J Clin Oncol 2010; 28(18 Suppl.): CRA3507.
85. Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, et al. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist 2011; 16: 1557-64. http://dx. doi. org/10. 1634/theoncologist. 2011-0141.
86. Baker JB, Dutta D, Watson D, Maddala T, Shak S, Rowinsky EK, et al. Evaluation of tumor gene expression and K-RAS mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26(15 Suppl.): 3512.
87. Baloglu H, Yilmaz I, Kucukodaci Z. A KRAS mutation profile in colorectal carcinomas: mutation detection technique may affect patient selection for anti-EGFR therapy. Lab Invest 2012; 92: 155A.
88. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008; 26(15 Suppl.): 4000.
89. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud F, Schuch G, Zubel A, et al. Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4 ± cetuximab as 1st-line treatment for metastatic colorectal cancer: the OPUS study. Ejc Suppl 2009; 7: 346. http://dx. doi. org/10. 1016/S1359-6349(09)71174-7.
90. Bokemeyer C, Kohne C, Rougier P, Stroh C, Schlichting M, Van Cutsem E. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. J Clin Oncol 2010; 28(15 Suppl.): 3506.
91. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466-75. http://dx. doi. org/10. 1016/j. ejca. 2012. 02. 057.
92. Chuko J, Yeh MK, Chen BJ, Hu KY. Efficacy of cetuximab on wild-type and mutant KRAS in colorectal cancer: systematic review and meta-analysis. J Med Sci 2010; 30: 189-98.
93. Cohen D, Ma H, Yuan Y, Hochman T, Hochster HS. Biweekly cetuximab (C), oxaliplatin (Ox), and capecitabine (Cape) in first line therapy of metastatic colorectal cancer (mCRC): preliminary results on toxicity and K-RAS status. J Clin Oncol 2008; 26(15 Suppl.): 15060.
94. Colucci G, Giuliani F, Garufi C, Mattioli R, Manzione L, Russo A, et al. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale multicenter phase II study. Oncology 2010; 79: 415-22. http://dx. doi. org/10. 1159/000323279.
95. Di Salvatore M, Inno A, Orlandi A, Martini M, Nazzicone G, Ferraro D, et al. KRAS and BRAF mutational status and PTEN, cMET, and IGF1R expression as predictive markers of response to cetuximab plus chemotherapy in metastatic colorectal cancer (mCRC). J Clin Oncol 2010; 28(Suppl 1): e14065.
96. Dubus P, Berhouet S, Carrere N, Merlio JP. Predicting response to anti-EGFR therapy for colorectal carcinoma by KRAS mutation testing. Cytometry Part B 2009; 76B: 420-1.
97. Folprecht G, Kohne CH. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. Adv Gastrointest Cancers 2008; 6: 13-14.
98. Folprecht G, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, et al. Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): a quality-of-life (QoL) analysis of the CRYSTAL trial. J Clin Oncol 2009; 27(155 Suppl.): 4076.
99. Folprecht G, Kohne C, Bokemeyer C, Rougier P, Schlichting M, Heeger S, et al. Cetuximab and 1st-line chemotherapy in elderly and younger patients with metastatic colorectal cancer (MCRC): a pooled analysis of the crystal and opus studies. Ann Oncol 2010; 21: 194.
100. Gajate P, Sastre J, Bando I, Alonso T, Cillero L, Sanz J, et al. Influence of KRAS p. G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. Clin Colorectal Cancer 2012; 11: 291-6. http://dx. doi. org/10. 1016/j. clcc. 2012. 02. 003.
101. Gao J, Wang TT, Yu JW, Li YY, Shen L. Wild-type KRAS and BRAF could predict response to cetuximab in Chinese colorectal cancer patients. Chinese J Cancer Res 2011; 23: 271-5. http://dx. doi. org/10. 1007/s11670-011-0271-4.
102. Garufi C, Torsello A, Tumolo S, Mottolese M, Melucci E, Campanella C, et al. Induction of resectability of colorectal liver metastases (CLM) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) (POCHER trial). Eur J Cancer 2009; 7: 348. http://dx. doi. org/10. 1016/S1359-6349(09)71181-4.
103. Goldberg RM, Sargent DJ, Thibodeau SN, Mahoney MR, Shields AF, Chan E, et al. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 2010; 28(15 Suppl.): 3508.
104. Griebsch I, Lang I, Sartorius U, Van Cutsem E. The effect of tumor response on quality of life (QoL) in patients with KRAS wild-type metastatic colorectal cancer (mCRC): analysis from the CRYSTAL study. J Clin Oncol 2011; 29(15 Suppl.): 3626.
105. Harbison CT, Horak CE, Ledeine JM, Mukhopadhyay P, Malone DP, O'Callaghan C, et al. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO. 17 trial published online ahead of print 3 October 2012. Arch Pathol Lab Med 2012. doi: 10. 5858/arpa. 2012-0367-OA. http://dx. doi. org/10. 5858/arpa. 2012-0367-OA.
106. Huang J, Sargent DJ, Mahoney MR, Thibodeau SN, Smyrk TC, Sinicrope F, et al. Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147. J Clin Oncol 2011; 29(4 Suppl.): 363.
107. Ibrahim EM, Zekri JM, Bin Sadiq BM. Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-RAS mutations. Int J Colorectal Dis 2010; 25: 713-21. http://dx. doi. org/10. 1007/s00384-010-0927-4.
108. Jones C, Taylor MA, McWilliams B. The role of cetuximab as first-line treatment of colorectal liver metastases. HPB (Oxford) 2013; 15: 11-17. http://dx. doi. org/10. 1111/j. 1477-2574. 2012. 00591. x.
109. Jonker DJ, Karapetis C, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, et al. High epiregulin (EREG) gene expression plus K-RAS wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): results from NCIC CTG CO. 17-A phase III trial of cetuximab versus best supportive care (BSC). J Clin Oncol 2009; 27(155 Suppl.): 4016.
110. Kimura T, Okamoto K, Miyamoto H, Kimura M, Kitamura S, Takenaka H, et al. Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy. Oncology (Switzerland) 2012; 82: 298-304.
111. Kohne C, Stroiakovski D, Chang-chien C, Lim R, Pinter T, Bodoky G, et al. Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. J Clin Oncol 2009; 27(155 Suppl.): 4068.
112. Ku GY, Haaland BA, de Lima Lopes G Jr. Cetuximab in the first-line treatment of K-RAS wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters. Cancer Chemother Pharmacol 2012; 70: 231-8. http://dx. doi. org/10. 1007/s00280-012-1898-7.
113. Lang I, Kohne CH, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, et al. Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial. Eur J Cancer 2009; 7: 345. http://dx. doi. org/10. 1016/S1359-6349(09)71173-5.
114. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-5. http://dx. doi. org/10. 1158/0008-5472. CAN-06-0191.
115. Lin OSR. Activating KRAS mutations as an independent predictor in metastatic colorectal cancer patients treated with cetuximab. Ann Oncol 2010; 21: i36.
116. Lin AY, Buckley NS, Lu A-TT, Kouzminova NB, Salpeter SR. Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. Clin Colorectal Cancer 2011; 10: 63-9. http://dx. doi. org/10. 3816/CCC. 2011. n. 009.
117. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9: 962-2. http://dx. doi. org/10. 1016/S1470-2045 (08)70206-7.
118. Loupakis F, Cremolini C, Salvatore L, Schirripa M, Lonardi S, Vaccaro V, et al. Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. Cancer 2012; 118: 1523-32. http://dx. doi. org/10. 1002/cncr. 26460.
119. Malapelle U, Bellevicine C, Salatiello M, De Luca C, Rispo E, Riccio P, et al. Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective. J Clin Pathol 2012; 65: 940-4. http://dx. doi. org/10. 1136/jclinpath-2012-200773.
120. Malapelle U, Carlomagno C, Salatiello M, De Stefano A, De Luca C, Bianco R, et al. KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. Br J Cancer 2012; 107: 626-31. http://dx. doi. org/10. 1038/bjc. 2012. 275.
121. Mancuso A, Leone A, Vigna L, Calabro F, Giuliani R, De Marco S, et al. EGFR, DCC, and K-RAS mutations as predictive factors for cetuximab sensitivity in metastatic colorectal cancer (mCRC). J Clin Oncol 2008; 26(155 Suppl.): 4128.
122. Maughan T, Adams RA, Smith CG, Seymour MT, Wilson R, Meade AM, et al. Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). Eur J Cancer 2009; 7: 4-5. http://dx. doi. org/10. 1016/S1359-6349(09)72034-8.
123. Maughan TS, Adams R, Smith CG, Seymour MT, Wilson RH, Meade AM, et al. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): mature results of the MRC COIN trial. J Clin Oncol 2010; 28(15 Suppl.): 3502.
124. Maughan T, Adams R, Smith C, Seymour M, Wilson R, Meade A, et al. The addition of cetuximab to oxaliplatinfluoropyrimidine chemotherapy in first-line advanced colorectal cancer in the MRC COIN trial: identification of potentially responsive subsets of patients. Ann Oncol 2010; 21: vi17-18.
125. Mayer B, Bogner A, Jauch KW, Singer T. KRAS/BRAF mutation status as a predictive biomarker for anti-EGFR antibody therapy in primary and metastatic colorectal carcinoma. Onkologie 2010; 33: 151.
126. Merck KGaA. Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer (CRYSTAL). NCT00154102. Bethesda, MD: National Library of Medicine; 2011. URL: http://ClinicalTrials. gov/show/NCT00154102 (accessed 23 May 2013).
127. Modest DP, Brodowicz T, Stintzing S, Jung A, Neumann J, Laubender RP, et al. Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. Oncology (Switzerland) 2012; 83: 241-7.
128. Molinari FM, Felicioni LF, Buscarino MB, De Dosso SD, Buttitta FB, Malatesta SM, et al. High sensitive methods to identify K-RAS mutations increase the detection of non-responder metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. Ann Oncol 2010; 21: I33-4.
129. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104-a randomized trial of the German AIO CRC study group. J Clin Oncol 2011; 29: 1050-8. http://dx. doi. org/10. 1200/JCO. 2010. 31. 1936.
130. Ocvirk J, Vrbanec D, Beslija S, Koza I, Ciuleanu T, Papamichael D, et al. Relationship between KRAS status and efficacy of FOLFOX6 + cetuximab or FOLFIRI + cetuximab in first-line treatment of patients with metastatic colorectal cancer (MCRC): the CECOG/CORE1. 2. 001 trial. Ann Oncol 2009; 20(Suppl. 7): 17.
131. Passardi A, Ulivi P, Valgiusti M, Scarpi E, Moscati R, Chiadini E, et al. The role of KRAS, BRAF, and PI3K mutations as markers of resistance to cetuximab in metastatic colorectal cancer. J Clin Oncol 2011; 29(15 Suppl. 1): 3603.
132. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis 2011; 26: 823-33. http://dx. doi. org/10. 1007/s00384-011-1149-0.
133. Petrelli F, Barni S. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis 2012; 27: 997-1004. http://dx. doi. org/10. 1007/s00384-012-1438-2.
134. Piessevaux H, Schlichting M, Heeger S, Van Cutsem E, Tejpar S. Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (MCRC): analysis from the CRYSTAL study. Ann Oncol 2010; 21: viii193-4.
135. Piessevaux H, Van Cutsem E, Bokemeyer C, Schlichting M, Heeger S, Tejpar S. Early tumor shrinkage and long-term outcome in metastatic colorectal cancer (mCRC): assessment of predictive utility across treatment arms in the CRYSTAL and OPUS studies. J Clin Oncol 2011; 29(15 Suppl.): 3572.
136. Piessevaux H, Bokemeyer C, Schlichting M, Heeger S, Tejpar S. Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: lessons from the OPUS trial. J Clin Oncol 2011; 29(4 Suppl.): 398.
137. Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer 2010; 46: 2781-7. http://dx. doi. org/10. 1016/j. ejca. 2010. 05. 022.
138. Raoul JL, Van Laethem JL, Peeters M, Brezault C, Husseini F, Cals L, et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 2009; 9: 112. http://dx. doi. org/10. 1186/1471-2407-9-112.
139. Rivera F, Gravalos C, Massuti B, Puente J, Marcuello E, Valladares M, et al. Cetuximab plus capecitabine as first-line treatment for elderly patients (pts) with advanced colorectal cancer (mCRC). Final analysis of activity and survival according to KRAS status-the TTD-06-01 Spanish Cooperative Group trial. Eur J Cancer 2009; 7: 216. http://dx. doi. org/10. 1016/S1359-6349(09)70738-4.
140. Rose JS, Serna DS, Martin LK, Li X, Weatherby LM, Abdel-Misih S, et al. Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. Cancer 2012; 118: 6243-52. http://dx. doi. org/10. 1002/cncr. 27666.
141. Salazar R, Mini E, Folprecht G, Subtil F, van Laethem J, Thaler J, et al. Adjuvant FOLFOX4 plus or minus cetuximab (CMAB) in patients with KRAS mutant (MKRAS) resected stage III colon cancer (CC). Results from the PETACC8 Intergroup trial. Ann Oncol 2012; 23: 178-9.
142. Schuch G, Bondarenko I, Hartmann J, De Braud F, Volovat C, Nippgen J, et al. The OPUS study: predictive value of KRAS status on clinical outcome in patients with metastatic colorectal cancer treated with either FOLFOX4 or FOLFOX4 plus cetuximab. Ann Oncol 2008; 19: 18.
143. Serna DS, Martin LK, Li X, Weatherby LM, Rose JS, Bekaii-Saab T. Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinomas. J Clin Oncol 2011; 29(4 Suppl.): 388.
144. Shinozaki E, Bando H, Nishina T, Yamazaki K, Kadowaki S, Yuki S, et al. Clinical outcome of cetuximab for metastatic colorectal cancer patients harboring KRAS codon61, KRAS codon146, BRAF, NRAS OR PIK3CA mutations. Ann Oncol 2012; 23: 196-7.
145. Simon I, Tian S, Moreno V, Roepman P, Tabernero J, Snel M, et al. The role of activating mutations of KRAS, BRAF, and PIK3CA pathway convergence at the transcriptional level and prediction of treatment response to cetuximab in colorectal cancer. J Clin Oncol 2011; 29(15 Suppl.): 3534.
146. Stenger M. Cetuximab plus FOLFIRI in first-line treatment of KRAS mutation-negative, EGFR-positive metastatic colorectal cancer. Community Oncol 2012; 9: 304-6. http://dx. doi. org/10. 1016/j. cmonc. 2012. 09. 006.
147. Stintzing S, Jung A, Vehling-Kaiser U, Stauch M, Hass H, Dietzfelbinger H, et al. Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (MCRC): analysis of the randomized trial of the German AIO CRC study group: KRK-0204. Ann Oncol 2010; 21: viii189-90.
148. Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, et al. Adjuvant FOLFOX4 ± cetuximab in KRAS wild-type patients with resected stage III colon cancer results from the PETACC8 Intergroup Trial. Ann Oncol 2012; 23: 17.
149. Tejpar S, Bokemeyer C, Celik I, Schlichting M, Sartorius U, Van Cutsem E. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2011; 29(15 Suppl.): 3511.
150. Tejpar S, Bokemeyer C, Celik I, Schlichting M, Van Cutsem E. The role of the KRAS G13D mutation in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy plus cetuximab. J Clin Oncol 2011; 29(4 Suppl.): 630.
151. Tejpar S, Bokemeyer C, Celik I, Schlichting M, Heeger S, Van Cutsem E. KRAS mutations and outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. Ann Oncol 2011; 22: v16-17.
152. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-7. http://dx. doi. org/10. 1200/JCO. 2012. 42. 2592.
153. Tsoukalas N, Bagos P, Hamodrakas S. Multivariant metal-analysis of KRAS mutations's predictive value for response to cetuximab in colorectal cancer. Ann Oncol 2010; 21: 66.
154. Tsoukalas N, Tzovaras A, Tolia M, Papakostidi A, Kostakis I, Ardavanis A, et al. The efficacy of cetuximab and mutations of the KRAS gene in colorectal cancer. Arch Hellenic Med 2011; 28: 674-9.
155. Tsoukalas N, Tzovaras AA, Tolia M, Kostakis ID, Papakostidi A, Pistamaltzian N, et al. Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer. J BUON 2012; 17: 73-8.
156. Tveit K, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the Nordic VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. Ann Oncol 2010; 21: viii9.
157. Tveit K, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. J Clin Oncol 2011; 29(4 Suppl.): 365.
158. Ubago R, Castillo MA, Flores S, Rodriguez R, Beltran C. Cetuximab for the first-line treatment of metastatic colorectal cancer. Value Health 2011; 14: A433-4. http://dx. doi. org/10. 1016/j. jval. 2011. 08. 1104.
159. Vale C, Tierney JF, Meade A, Fisher D, Kaplan R, Adams RA, et al. Impact of K-RAS status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): a systematic review and meta-analysis of randomized controlled trials (RCTs). J Clin Oncol 2009; 27(155 Suppl.): 4122.
160. Van Cutsem E, Lang I, D'Haens G, Moiseyenko V, Zaluski J, Folprecht G, et al. KRAS status and efficacy in the crystal study: 1st-line treatment of patients with metastatic colorectal cancer (MCRC) receiving FOLFIRI with or without cetuximab. Ann Oncol 2008; 19: viii4.
161. Van Cutsem E, Rougier P, Kohne C, Stroh C, Schlichting M, Bokemeyer C. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): results according to KRAS and BRAF mutation status. Eur J Cancer Suppl 2009; 7: 345. http://dx. doi. org/10. 1016/S1359-6349(09) 71172-3.
162. Van Cutsem E, Lang I, Folprecht G, Nowacki M, Barone C, Shchepotin I, et al. Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. J Clin Oncol 2010; 28(15 Suppl.): 3570.
163. Van Cutsem E, Rougier P, Lang I, Folprecht G, Nowacki M, Barone C, et al. The influence of KRAS and BRAF tumor mutation status on treatment outcome with cetuximab plus FOLFIRI: final data from the CRYSTAL study. Ann Oncol 2010; 21: vi18.
164. Van Cutsem E, Kohne C-H, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-19. http://dx. doi. org/10. 1200/JCO. 2010. 33. 5091.
165. Wasan H, Adams RA, Wilson RH, Pugh CA, Fisher D, Madi A, et al. Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): results of the two-arm phase II randomised MRC COIN-B trial. Eur J Cancer 2011; 47: S393. http://dx. doi. org/10. 1016/S0959-8049(11)71651-3.
166. Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009; 11: 543-52. http://dx. doi. org/10. 2353/jmoldx. 2009. 090057.
167. Yen L-C, Uen Y-H, Wu D-C, Lu C-Y, Yu F-J, Wu IC, et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 2010; 251: 254-60. http://dx. doi. org/10. 1097/SLA. 0b013e3181bc9d96.
168. Zhang L, Ma L, Zhou Q. Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis. Int J Colorectal Dis 2011; 26: 1025-33. http://dx. doi. org/10. 1007/s00384-011-1197-5.